AstraZeneca stock price forecast: bullish setup intact as AZN targets Ichimoku Kijun resistance

Traders Union
All News
Financial News
AstraZeneca rises 0.67% to GBX 14,120

Highlights

AstraZeneca reported quarterly earnings of $1.19 per share on revenue of $15.19 billion, both exceeding consensus estimates.
The company completed the acquisition of Modella AI to strengthen its oncology research and development capabilities.
Recent share purchases in AstraZeneca were disclosed by Representatives Gilbert Ray Cisneros, Jr. and Julia Letlow.

Earnings beat and oncology acquisition support renewed investor interest

AstraZeneca recently reported quarterly earnings of $1.19 per share on revenue of $15.19 billion, surpassing consensus estimates. The company has also completed the acquisition of Modella AI to enhance its oncology research and development. Additional context includes recent share purchases by Representatives Gilbert Ray Cisneros, Jr. and Julia Letlow.

Sustained uptrend with strong momentum but overbought signals emerge

Momentum remains strong with a bullish signal from both the MACD and high ADX levels, indicating persistent upward strength. While the RSI and CCI suggest conditions are not yet overbought, Stochastic RSI and Bull/Bear Power flag overbought momentum with buyers dominating but with some risk of short-term exhaustion. The Awesome Oscillator supports the prevailing uptrend.

Upside favored as volatility persists and breakout scenarios develop

For the next five trading days, the expected price range is GBX 13,900 to GBX 14,800, reflecting typical volatility band relative to current levels. The probabilities favor a price increase, with a very high probability (more than 80%) for continued gains, while the likelihood of a decline is very low. The baseline scenario sees AZN remaining in a sideways corridor with minor fluctuations. A bullish scenario envisions a break above the Ichimoku Kijun, clearing GBX 14,400 and targeting higher resistance levels, while a bearish scenario unfolds if price falls below MA-50 support, exposing GBX 13,650 and potentially deeper retracement.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca sustaining a broadly bullish technical posture, with strong momentum supported by positive earnings and strategic acquisition news. He remains defensive, however, noting pockets of overbought risk and flagging MA-50 as a critical support zone for the current move. Kharitonov identifies base-case sideways action but warns of downside if MA-50 breaks. "Until GBX 14,400 is cleared with conviction and MA-50 holds, I remain cautious and prefer to wait for clearer direction."

Previously it was reported that AstraZeneca PLC remains in a strong bullish trend, trading above all key moving averages with positive momentum supported by MACD and ADX, though short-term oscillators indicate overbought conditions. The price is expected to consolidate within a defined volatility band, with dynamic resistance near the Ichimoku Kijun and support at the MA-50, as sustained buyer strength limits downside risk.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.